Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Erlotinib in Relapsed/Refractory GBM and AA
NCT00301418Phase 2Completed
- Sponsor
- Northwell Health
- Start
- Mar 2006
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) and anaplastic oligoastrocytoma (AOA), sponsored by Northwell Health. Primary endpoint: Safety of Twice a Day Oral 150 mg Erlotinib Dosing. Started Mar 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
glioblastoma multiforme (GBM)anaplastic astrocytoma (AA)anaplastic oligoastrocytoma (AOA)
Beyond the preview
Go deeper on NCT00301418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00301418.